Based on studies conducted at the US Army Medical Research Institute for Infectious Diseases, the FDA has approved Aethlon Medical’s Hemopurifier as an emergency intervention for Ebola patients. Studies of the Hemopurifier in Ebola-infected monkey blood and cell cultures demonstrated efficacy in binding and extracting the virus from blood. The Hemopurifier has been in clinical trials in India since 2007 and recently cured 5 out of 7 genotype 1 patients with hepatitis-C.
Developed to treat hepatitis-C and HIV, the Hemopurifier filters viruses and immunosuppressive proteins from infected blood through a bundle of hollow porous fibers enclosed in a cylindrical plastic case. Plasma fractions are pushed through a porous membrane by a blood pump, leaving the cellular blood components inside the fibers. When the virus passes through the pores of the membrane, it is absorbed just outside the fibers by affinity resins. Then the plasma re-enters the fibers, recombines with the blood, and is reintroduced into the patient at a much lower viral titer.
The Hemopurifier functions something like an artificial kidney and reduces viral load faster than drug therapy. The diminished viral load weakens the infection’s potential to overcome the immune system. Emergency authorization from the German government recently enabled Hemopurifier treatment of an Ebola-infected patient in Germany.